Iovance Biotherapeutics (IOVA) Short Interest Ratio & Short Volume $2.24 +0.02 (+0.67%) As of 09:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Iovance Biotherapeutics Short Interest DataIovance Biotherapeutics (IOVA) has a short interest of 67.71 million shares, representing 23.02% of the float (the number of shares available for trading by the public). This marks a -31.35% decrease in short interest from the previous month. The short interest ratio (days to cover) is 3.5, indicating that it would take 3.5 days of the average trading volume of 13.67 million shares to cover all short positions.Current Short Interest67,710,000 sharesPrevious Short Interest98,630,000 sharesChange Vs. Previous Month-31.35%Dollar Volume Sold Short$174.01 millionShort Interest Ratio3.5 Days to CoverLast Record DateJuly 31, 2025Outstanding Shares361,850,000 sharesFloat Size294,190,000 sharesShort Percent of Float23.02%Today's Trading Volume67,798 sharesAverage Trading Volume13,668,987 sharesToday's Volume Vs. Average0% Short Selling Iovance Biotherapeutics? Sign up to receive the latest short interest report for Iovance Biotherapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Get Report View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartIOVA Short Interest Over TimeIOVA Days to Cover Over TimeIOVA Percentage of Float Shorted Over Time Iovance Biotherapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 7/31/202567,710,000 shares $174.01 million -31.4%23.0%3.5 $2.57 7/15/202598,630,000 shares $191.34 million +1.9%36.3%5.7 $1.94 6/30/202596,780,000 shares $166.46 million +6.4%35.7%7.1 $1.72 6/15/202590,960,000 shares $203.75 million +5.3%33.5%6.9 $2.24 5/31/202586,360,000 shares $151.30 million +12.1%31.8%6.7 $1.75 5/15/202577,020,000 shares $135.56 million +3.3%28.4%5.8 $1.76 4/30/202574,570,000 shares $267.71 million +4.5%27.6%6.3 $3.59 4/15/202571,370,000 shares $230.53 million -5.1%26.9%7.4 $3.23 3/31/202575,190,000 shares $250.38 million +11.7%28.3%7.6 $3.33 3/15/202567,300,000 shares $241.61 million +12.9%25.3%7.2 $3.59 Get the Latest News and Ratings for IOVA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/28/202559,590,000 shares $252.66 million -6.3%22.4%6.7 $4.24 2/15/202563,600,000 shares $354.25 million -0.5%25.7%8.6 $5.57 1/31/202563,910,000 shares $373.87 million +3.1%26.0%7.8 $5.85 1/15/202561,980,000 shares $366.30 million +1.1%25.1%8.1 $5.91 12/31/202461,310,000 shares $453.69 million +3.3%24.8%8.9 $7.40 12/15/202459,330,000 shares $464.55 million +4.2%24.0%9.6 $7.83 11/30/202456,920,000 shares $530.49 million +5.4%23.1%9.3 $9.32 11/15/202453,990,000 shares $441.64 million -9.6%21.9%8.6 $8.18 10/31/202459,730,000 shares $623.58 million -1.0%24.1%10.2 $10.44 10/15/202460,340,000 shares $578.66 million +0.7%24.4%10.1 $9.59 9/30/202459,950,000 shares $562.93 million -0.6%24.3%9.7 $9.39 9/15/202460,290,000 shares $623.40 million +4.5%24.4%8.9 $10.34 8/31/202457,690,000 shares $672.67 million -2.8%23.3%8 $11.66 8/15/202459,330,000 shares $633.05 million -3.3%24.5%8 $10.67 7/31/202461,320,000 shares $535.32 million +4.0%27.4%8.3 $8.73 7/15/202458,940,000 shares $511.60 million +4.5%26.4%9 $8.68 6/30/202456,420,000 shares $452.49 million +3.3%25.2%9 $8.02 6/15/202454,630,000 shares $445.78 million +9.4%24.4%9.3 $8.16 5/31/202449,960,000 shares $443.64 million -2.4%22.3%8.5 $8.88 5/15/202451,210,000 shares $546.92 million +2.3%22.9%7.8 $10.68 4/30/202450,060,000 shares $589.71 million +2.2%22.6%5.7 $11.78 4/15/202448,980,000 shares $582.37 million +5.6%22.2%5.5 $11.89 3/31/202446,380,000 shares $687.35 million -2.2%21.1%4.9 $14.82 3/15/202447,430,000 shares $659.75 million +1.5%21.6%4.6 $13.91 2/29/202446,710,000 shares $743.16 million +8.7%21.2%4.5 $15.91 2/15/202442,980,000 shares $424.21 million +2.4%20.1%4.4 $9.87 1/31/202441,970,000 shares $324.43 million -3.0%21.0%5.6 $7.73 1/15/202443,270,000 shares $389.86 million +18.8%21.7%5.7 $9.01 12/31/202336,410,000 shares $296.01 million +3.2%18.2%4.8 $8.13 12/15/202335,280,000 shares $274.48 million +2.0%17.7%5.1 $7.78The Coin That Could Define Trump’s Crypto Presidency (Ad)When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”Discover the coin that could define Trump’s crypto presidency. 11/30/202334,590,000 shares $209.96 million -2.8%17.5%4.7 $6.07 11/15/202335,590,000 shares $169.05 million -8.4%18.0%5.2 $4.75 10/31/202338,860,000 shares $148.45 million +0.3%19.4%6 $3.82 10/15/202338,740,000 shares $140.63 million +5.4%19.4%6.4 $3.63 9/30/202336,770,000 shares $167.30 million +20.5%18.4%6 $4.55 9/15/202330,510,000 shares $160.79 million +1.5%15.3%4.9 $5.27 8/31/202330,070,000 shares $181.62 million +9.2%14.7%6.2 $6.04 8/15/202327,530,000 shares $206.75 million -0.1%13.5%4.6 $7.51 7/31/202327,550,000 shares $200.01 million +6.1%13.6%4.6 $7.26 7/15/202325,960,000 shares $201.45 million -10.1%13.1%4.4 $7.76 6/30/202328,890,000 shares $203.39 million +12.8%14.6%5.1 $7.04 6/15/202325,620,000 shares $221.36 million +18.3%14.1%4.8 $8.64 5/31/202321,650,000 shares $189.22 million -7.4%11.9%4.4 $8.74 5/15/202323,380,000 shares $183.30 million No Change12.9%5.9 $7.84 10/31/202217,260,000 shares $161.21 million -5.0%12.2%8 $9.34 10/15/202218,170,000 shares $160.80 million -2.6%12.7%8.2 $8.85 9/30/202218,660,000 shares $178.76 million -4.5%13.0%8 $9.58 9/15/202219,540,000 shares $231.94 million -0.6%13.7%6.5 $11.87 8/31/202219,650,000 shares $210.65 million -5.4%13.7%5.6 $10.72 8/15/202220,760,000 shares $266.77 million +6.9%14.5%4.1 $12.85 7/31/202219,420,000 shares $226.24 million -2.6%14.0%3.8 $11.65 7/15/202219,940,000 shares $255.23 million -7.5%14.3%4.1 $12.80 6/30/202221,550,000 shares $237.91 million +30.1%15.5%4.4 $11.04 6/15/202216,560,000 shares $135.79 million -4.7%11.9%3.5 $8.20 5/31/202217,370,000 shares $117.25 million +1.0%12.5%4.6 $6.75 5/15/202217,200,000 shares $242.00 million +8.8%12.4%8.2 $14.07 4/30/202215,810,000 shares $239.52 million +3.7%11.4%7.7 $15.15 4/15/202215,250,000 shares $268.71 million +9.9%11.0%7.3 $17.62 3/31/202213,880,000 shares $231.10 million +1.5%N/A6.3 $16.65 3/15/202213,680,000 shares $171.14 million -0.3%9.9%6.7 $12.51 2/28/202213,720,000 shares $214.99 million +9.4%10.1%7 $15.67 2/15/202212,540,000 shares $223.96 million +11.6%9.2%6.3 $17.86 1/31/202211,240,000 shares $187.15 million -6.5%8.3%5.3 $16.65 1/15/202212,020,000 shares $186.19 million -3.6%N/A5.7 $15.49 12/31/202112,470,000 shares $238.05 million -6.9%9.1%6.7 $19.09 12/15/202113,390,000 shares $247.85 million -14.3%9.8%7.9 $18.51 11/30/202115,620,000 shares $292.41 million -1.1%11.5%9.5 $18.72 11/15/202115,800,000 shares $309.52 million +3.7%11.6%10.2 $19.59 10/29/202115,230,000 shares $370.24 million +0.3%11.1%11.2 $24.31 10/15/202115,190,000 shares $404.21 million +3.8%11.2%11.2 $26.61 9/30/202114,640,000 shares $361.02 million -5.5%10.8%10 $24.66 9/15/202115,490,000 shares $372.22 million -6.7%11.5%9.4 $24.03 8/31/202116,600,000 shares $399.56 million -2.0%12.3%9 $24.07 8/13/202116,940,000 shares $368.78 million -1.7%12.5%7.5 $21.77 7/30/202117,240,000 shares $383.93 million -3.5%12.7%4.8 $22.27 7/15/202117,860,000 shares $402.39 million +0.7%12.7%4.9 $22.53 6/30/202117,730,000 shares $461.33 million -14.4%12.6%4.8 $26.02 6/15/202120,720,000 shares $490.65 million -7.2%14.7%5.5 $23.68 5/28/202122,330,000 shares $414.67 million +11.0%15.9%6.1 $18.57 5/14/202120,120,000 shares $503.20 million +1.9%N/A5.8 $25.01The Coin That Could Define Trump’s Crypto Presidency (Ad)When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”Discover the coin that could define Trump’s crypto presidency. 4/30/202119,750,000 shares $618.97 million -1.5%N/A9.7 $31.34 4/15/202120,040,000 shares $601.00 million -6.0%N/A10.8 $29.99 3/31/202121,320,000 shares $631.92 million +43.3%N/A12 $29.64 3/15/202114,880,000 shares $516.19 million +6.4%N/A10.1 $34.69 2/26/202113,980,000 shares $510.41 million +9.4%N/A10 $36.51 2/12/202112,780,000 shares $610.25 million -9.0%N/A10.3 $47.75 1/29/202114,050,000 shares $613.28 million -8.4%N/A11.7 $43.65 1/15/202115,340,000 shares $798.14 million -1.2%N/A12.8 $52.03 12/31/202015,530,000 shares $757.24 million -5.4%N/A12 $48.76 12/15/202016,410,000 shares $824.77 million -2.2%N/A10.9 $50.26 11/30/202016,780,000 shares $660.80 million +1.3%N/A12.1 $39.38 11/15/202016,570,000 shares $625.02 million -0.1%N/A11.7 $37.72 10/30/202016,590,000 shares $595.25 million +9.4%N/A11.9 $35.88 10/15/202015,160,000 shares $524.54 million +17.3%N/A10.9 $34.60 9/30/202012,920,000 shares $425.33 million -7.0%N/A10.2 $32.92 9/15/202013,890,000 shares $496.15 million -4.6%N/A10.4 $35.72 8/31/202014,560,000 shares $485.28 million +1.0%N/A10 $33.33 IOVA Short Interest - Frequently Asked Questions What is Iovance Biotherapeutics' current short interest? Short interest is the volume of Iovance Biotherapeutics shares that have been sold short but have not yet been covered or closed out. As of July 31st, traders have sold 67,710,000 shares of IOVA short. 23.02% of Iovance Biotherapeutics' shares are currently sold short. Learn More on Iovance Biotherapeutics' current short interest. What is a good short interest ratio for Iovance Biotherapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IOVA shares currently have a short interest ratio of 4.0. Learn More on Iovance Biotherapeutics's short interest ratio. Which institutional investors are shorting Iovance Biotherapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Iovance Biotherapeutics: Group One Trading LLC, Jane Street Group LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Iovance Biotherapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 23.02% of Iovance Biotherapeutics' floating shares are currently sold short. Is Iovance Biotherapeutics' short interest increasing or decreasing? Iovance Biotherapeutics saw a drop in short interest in the month of July. As of July 31st, there was short interest totaling 67,710,000 shares, a drop of 31.3% from the previous total of 98,630,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Iovance Biotherapeutics' float size? Iovance Biotherapeutics currently has issued a total of 361,850,000 shares. Some of Iovance Biotherapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Iovance Biotherapeutics currently has a public float of 294,190,000 shares. How does Iovance Biotherapeutics' short interest compare to its competitors? 23.02% of Iovance Biotherapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Iovance Biotherapeutics: Mirum Pharmaceuticals, Inc. (15.41%), Protagonist Therapeutics, Inc. (9.74%), MoonLake Immunotherapeutics (11.00%), Apellis Pharmaceuticals, Inc. (18.71%), Scholar Rock Holding Corporation (17.84%), Kymera Therapeutics, Inc. (14.17%), Xenon Pharmaceuticals Inc. (9.47%), Amneal Pharmaceuticals, Inc. (3.42%), Viking Therapeutics, Inc. (26.61%), Arrowhead Pharmaceuticals, Inc. (9.78%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), Strategy Inc ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks. What does it mean to sell short Iovance Biotherapeutics stock? Short selling IOVA is an investing strategy that aims to generate trading profit from Iovance Biotherapeutics as its price is falling. IOVA shares are trading down $0.19 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Iovance Biotherapeutics? A short squeeze for Iovance Biotherapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IOVA, which in turn drives the price of the stock up even further. How often is Iovance Biotherapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IOVA, twice per month. The most recent reporting period available is July, 31 2025. More Short Interest Resources from MarketBeat Related Companies MIRM Short Interest PTGX Short Interest MLTX Short Interest APLS Short Interest SRRK Short Interest KYMR Short Interest XENE Short Interest AMRX Short Interest VKTX Short Interest ARWR Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:IOVA) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Iovance Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access